Selank is a synthetic seven-amino-acid peptide derived from the immune-signaling molecule tuftsin, approved in Russia as an intranasal anxiolytic and used off-label for anxiety relief, cognitive support, and mood stabilization.
What it does
Selank starts from tuftsin, a naturally occurring peptide your immune system uses to regulate inflammation and immune cell activity. Researchers added a Pro-Gly-Pro tail to the tuftsin sequence to slow enzymatic breakdown, giving the resulting molecule time to act in the brain V 2018. The peptide works through several overlapping pathways rather than one single switch.
First, it raises BDNF (brain-derived neurotrophic factor) levels in the hippocampus and prefrontal cortex — regions central to memory and emotional regulation G 2019. BDNF drives neuroplasticity, the brain's capacity to rewire synaptic connections, so the anxiolytic effect here comes from structural adaptation rather than chemical sedation. Second, Selank modulates GABA-A receptors — the same receptors that benzodiazepines target — but does so by sensitizing them rather than directly activating them R 2021. The result is increased inhibitory tone without the sedation, cognitive blunting, or dependence liability that comes with benzo use. Third, it inhibits enkephalinase, the enzyme that degrades enkephalins (endogenous opioid peptides your body makes naturally), which gently raises endogenous opioid tone and contributes to anxiolysis and mild mood lift V 2018.
Selank also shows bidirectional IL-6 regulation — nudging this pro-inflammatory cytokine up when it is suppressed and down when it is elevated — a property that traces directly back to its tuftsin ancestry V 2018. Functional neuroimaging work suggests it alters connectivity patterns across brain networks in ways distinct from classical sedatives R 2020.
What the evidence shows
Anxiety reduction Moderate rodent evidence; limited but positive human data from Russian clinical trials; no large Western RCTs
Animal studies consistently show anxiolytic effects without sedation or motor impairment, mechanistically tied to GABAergic sensitization and BDNF upregulation R 2021. Russian clinical trials — the basis for Selank's approval as a nasal spray — reported reductions in generalized anxiety and improved emotional stability, though these studies are not widely indexed in Western literature and sample sizes are modest V 2018. No large, placebo-controlled trials conducted outside Russia have been published.
Cognitive protection and memory Rodent evidence is solid; human evidence is indirect
In rats, Selank reversed ethanol-induced memory impairment and restored BDNF levels in both the hippocampus and prefrontal cortex G 2019. Functional connectome analysis showed that Selank altered inter-regional brain communication patterns in ways associated with improved cognitive processing R 2020. No controlled human memory trials exist; extrapolation from rodent and neuroimaging data is reasonable but not confirmed.
Opioid and substance withdrawal support Early rodent evidence only
One 2022 study found Selank attenuated aversive behavioral signs of morphine withdrawal in rats, likely through enkephalinase inhibition raising endogenous opioid levels A 2022. This is intriguing mechanistically but has not been tested in humans. Treat this use case as hypothesis-generating, not established.
Immune modulation Mechanistic and preclinical; human data absent
Because Selank is structurally derived from tuftsin — a tetrapeptide that regulates macrophage and natural killer cell activity — it retains some immune-modulatory properties, including the bidirectional IL-6 normalization noted across multiple preclinical studies V 2018. Whether this translates into clinically meaningful immune effects in healthy humans remains untested.
How it's used
In Russian clinical use and self-reported protocols, Selank is administered intranasally — the approved and most common route. Doses range from 250 mcg twice daily (lower end) to 500 mcg two to three times daily (mid-range) to 900 mcg three times daily (higher end). Subcutaneous injection is also reported in self-experimenter communities, typically at similar microgram-level doses. The plasma half-life is approximately 30 minutes, but BDNF-mediated effects are thought to persist for hours beyond peak plasma levels V 2018. Timing is typically morning and early afternoon to avoid potential interference with sleep. Course lengths in Russian clinical practice have ranged from one to four weeks; long-term continuous use protocols have not been formally studied.
Side effects and safety
Reported side effects in both clinical and self-report contexts are mild. Nasal irritation is the most common complaint with intranasal use. Mild fatigue or transient drowsiness has been noted in some users, along with occasional headache R 2021. No severe adverse events have been documented in published literature. Because Selank enhances GABAergic tone without direct receptor agonism, the dependence and withdrawal profile appears distinct from benzodiazepines — but long-term use data in humans simply does not exist, so this cannot be stated with certainty R 2021. The peptide is contraindicated in pregnancy and in individuals with known hypersensitivity. Use in children is not studied. Long-term neurological effects, impact on BDNF regulation over extended periods, and interactions with psychiatric medications are all genuinely unknown.
Bottom line
Selank has a coherent, multi-pathway mechanism and credible Russian clinical approval behind it, but the evidence base available in English-language peer-reviewed literature is thin and largely preclinical. It is a reasonable candidate for anxiety reduction in people who want to avoid sedating agents, but anyone expecting Western-trial-grade confidence will not find it here.